<code id='89408218B9'></code><style id='89408218B9'></style>
    • <acronym id='89408218B9'></acronym>
      <center id='89408218B9'><center id='89408218B9'><tfoot id='89408218B9'></tfoot></center><abbr id='89408218B9'><dir id='89408218B9'><tfoot id='89408218B9'></tfoot><noframes id='89408218B9'>

    • <optgroup id='89408218B9'><strike id='89408218B9'><sup id='89408218B9'></sup></strike><code id='89408218B9'></code></optgroup>
        1. <b id='89408218B9'><label id='89408218B9'><select id='89408218B9'><dt id='89408218B9'><span id='89408218B9'></span></dt></select></label></b><u id='89408218B9'></u>
          <i id='89408218B9'><strike id='89408218B9'><tt id='89408218B9'><pre id='89408218B9'></pre></tt></strike></i>

          explore

          explore

          author:explore    Page View:261
          Photograph of Ron DeSantis pointing. -- health policy coverage from STAT
          Florida Gov. and GOP presidential candidate Ron DeSantis wants to import Canadian prescription drugs. Charlie Neibergall/AP

          WASHINGTON — Florida governor and presidential hopeful Ron DeSantis has ballyhooed a high-profile plan to import prescription drugs from Canada, even suing the Biden administration for allegedly holding up a necessary sign-off.

          But the plan’s long odds just got longer: the Food and Drug Administration said in a letter last week that Florida’s plan has gaping holes — and the state has less than a week to explain how it’ll fix them.

          advertisement

          The FDA “identified several deficiencies,” in the drug-import plan, it said. Despite its thousands of pages, the plan does not show whether it meets the two overarching requirements of saving money and securing the drug supply chain, the agency explained. The FDA gave the state until August 28 to flesh out those two subjects.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          Acelyrin, a rare IPO success, stumbles in its first big test
          Acelyrin, a rare IPO success, stumbles in its first big test

          MarkLennihan/APThebiotechcompanyAcelyrin,whichraisedmorethan$500millioninanIPOthisyear,ranintoitsfir

          read more
          Wildfire smoke exposes gaps in outdoor worker protections
          Wildfire smoke exposes gaps in outdoor worker protections

          ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

          read more

          Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

          LongtimeBluebirdBioCEONickLeschlyWendyMaeda/TheBostonGlobeSometwoyearsaftersplittingbiotechcompanyBl